Dantrolene (sodium hemiheptahydrate)

Base Information

• Chemical Name: Dantrolene (sodium hemiheptahydrate)
• CAS No.: 24868-20-0
• Molecular Formula: C14H9N4NaO5.7/2H2O
• Molecular Weight: 336.23
• Hs Code.: 2934990002
• European Community (EC) Number: 829-303-3
• DSSTox Substance ID: DTXSID401017218
• Mol file: 24868-20-0.mol

Synonyms:24868-20-0;Dantrolene Sodium Hydrate;Dantrolene (sodium hemiheptahydrate);DTXSID401017218;PD064949;FT-0603133;Sodium 3-({[5-(4-nitrophenyl)-2-furanyl]methylidene}amino)-2,5-dioxoimidazolidin-1-ide hydrate (2:2:7)

Chemical Property of Dantrolene (sodium hemiheptahydrate)

Chemical Property:

• Appearance/Colour: Orange powder
• Vapor Pressure: 1.09E-12mmHg at 25°C
• Melting Point: >230°C
• Boiling Point: 544.5°C at 760 mmHg
• Flash Point: 283.1°C
• PSA: 318.71000
• LogP: 2.97810
• Storage Temp.: -20°C Freezer
• Hydrogen Bond Donor Count: 7
• Hydrogen Bond Acceptor Count: 19
• Rotatable Bond Count: 6
• Exact Mass: 798.16808015
• Heavy Atom Count: 55
• Complexity: 536

Purity/Quality:

99%, ^*data from raw suppliers

DantroleneSodiumSaltHemiheptahydrate ^*data from reagent suppliers

Safty Information:

• Safety Statements: 22-24/25

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1C(=NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[O-].C1C(=NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[O-].O.O.O.O.O.O.O.[Na+].[Na+]
• Uses: A muscle relaxant (skeletal). Used in the treatment of malignant hyperthermia Dantrolene Sodium Salt Hemiheptahydrate is a muscle relaxant (skeletal). Used in the treatment of malignant hyperthermia.
• Therapeutic Function: Muscle relaxant
• Biological Functions: Dantrolene sodium (Dantrium) is used in the treatment of spasticity due to stroke, spinal injury, multiple sclerosis, or cerebral palsy. It is also the drug of choice in prophylaxis or treatment of malignant hyperthermia. Susceptibility to malignant hyperthermia is due to a rare genetic defect that allows Ca++ release from the sarcoplasmic reticulum to open more easily and close less readily than normal. This leads to a high level of Ca++ in the sarcoplasm, which produces muscle rigidity, oxygen consumption, and heat. Dantrolene acts by blocking Ca++ release from the sarcoplasmic reticulum and uncoupling excitation from contraction. Dantrolene is active orally, although its absorption is slow and incomplete. Its biological half-life (t1/2) is 8.7 hours in adults. The drug is metabolized by liver microsomal enzymes and is eliminated in the urine and bile. It is given IV when treating an attack of malignant hyperthermia. The most prominent and often limiting feature of dantrolene administration is dose-dependent muscle weakness. Other side effects are drowsiness, dizziness, malaise, fatigue, and diarrhea. Symptomatic hepatitis is reported in 0.5% of patients receiving it and fatal hepatitis in up to 0.2%. Contraindications include respiratory muscle weakness and liver disease. It is suggested that patients on dantrolene therapy be given regular liver function tests.
• Clinical Use: Oral: Treatment of chronic, severe spasticity of skeletal muscleIV: Treatment of malignant hyperthermia
• Drug interactions: Potentially hazardous interactions with other drugsAvoid with other hepatotoxic medication.